Tag

Cell and Gene Therapy

The Integrated Development and Manufacturing Organization: The Future of Cell Therapy Manufacturing
LIFE SCIENCES, LIFE SCIENCES, VIDEO

The Integrated Development and Manufacturing Organization: The Future of Cell Therapy Manufacturing

— John TomtishenVP OperationsCellares John Tomtishen is Vice President of Operations at Cellares Corporation. At Cellares, John is responsible for Cellares’ IDMO business, supporting partnership activities, and facilitating accelerated market adoption of Cellares’ Cell Shuttle technology to transform the cell therapy manufacturing paradigm and address industry bottlenecks to accelerate access to life saving cell therapies. John has extensive experience in cell and gene therapies, biologics, and vaccines with diverse roles in Business Operations, CMC/Technical Operations, R&D, Supply Chain, Engineering/Facilities, and Operational Excellence. While at Novartis Pharmaceuticals, John had an integral role in the filing and approval of the first CAR…

Continue reading
Technical Operations Strategies in an Uncertain Market
LIFE SCIENCES, LIFE SCIENCES, VIDEO

Technical Operations Strategies in an Uncertain Market

 State of the current market and impact on manufacturing cell and gene therapies Key factors to consider when scaling up a facility for advanced medicines Make vs. Buy and the advantages and challenges of both solutions given the current market Moderator: Adam Pfeiffer VP of Strategy Project Farma Adam Pfeiffer is the Vice President of Strategy at Project Farma. In his role, Adam drives overall business strategy, aligning with operations, marketing, and business development groups in growing the firm’s global life sciences partnerships.With 16+ years of life sciences consulting experience, Adam has supported countless drug manufacturers in bringing life-saving therapies…

Continue reading
How to Make the Bio-Revolution a Reality: Building Bayer’s Cell & Gene Therapy Platform
LIFE SCIENCES, LIFE SCIENCES, VIDEO

How to Make the Bio-Revolution a Reality: Building Bayer’s Cell & Gene Therapy Platform

How Bayer AG built its Cell & Gene Therapy unit New business model joining best of Biotech and best of Pharma How to build a sustainable pipeline? How to manage complexity and keep focus? What are the “must haves”? what are the learnings on common threats of significant transformations? New ways of working accelerated by COVID-19 pandemic Wolfram Carius EVP, Cell and Gene Therapy Bayer AG Prof. Wolfram Carius is the EVP, Cell and Gene Therapy at Bayer AG and is a member of the Executive Committee for Bayer Pharmaceuticals. He is based in Berlin, Germany. Prior to joining Bayer,…

Continue reading